<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Endo Pharmaceuticals Holdings</title>
	<atom:link href="http://www.stockbloghub.com/tag/endo-pharmaceuticals-holdings/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ENDP) Endo Pharmaceuticals Buys US Rights to Fortesta</title>
		<link>http://www.stockbloghub.com/2009/08/28/endp-endo-pharmaceuticals-buys-us-rights-to-fortesta/13788</link>
		<comments>http://www.stockbloghub.com/2009/08/28/endp-endo-pharmaceuticals-buys-us-rights-to-fortesta/13788#comments</comments>
		<pubDate>Fri, 28 Aug 2009 23:43:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings]]></category>
		<category><![CDATA[ENDP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13788</guid>
		<description><![CDATA[Endo Pharmaceuticals (ENDP) signed an agreement with UK-based ProStrakan Group Plc to acquire exclusive rights to commercialize Fortesta in the U.S., where the product is currently under Food and Drug Administration (FDA) review. Fortesta is a 2% testosterone transdermal gel for testosterone replacement therapy in male hypogonadism. The product uses a metered dose delivery system for adjustment of dosage according to individual needs. Fortesta is already available in Europe. Under terms of the deal, Endo will make an upfront payment of $10 million to ProStrakan and another $40 million by the end of 2010 on achievement of regulatory and commercial milestones. Endo has also agreed to pay an additional $160 million on realization of certain sales targets. ProStrakan will supply Fortesta to Endo in the U.S. for an undisclosed supply ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/28/endp-endo-pharmaceuticals-buys-us-rights-to-fortesta/13788/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

